Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Single-arm Study of Evofosfamide + Doxorubicin in Japanese Soft Tissue Sarcoma
jRCT2080222619Phase 2Completed
- Sponsor
- Merck Serono
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of evofosfamide in soft tissue sarcoma (STS), sponsored by Merck Serono. Started Oct 2014; status: completed.
02
Drugs
evofosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on jRCT2080222619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222619.